Amy K. Keating
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amy K. Keating has a total of 268 co-authors. Here are the top co-authors by number of shared publications:
Christine L. Phillips
Department of Pediatrics, Cancer and Blood Disease Institute, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH
7 shared publications- Crystal L. Mackall
Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
7 shared publications - Jenna Rossoff
Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
7 shared publications Michael R. Verneris
24University of Colorado, Anschutz Medical Campus, Colorado Children’s Hospital, Aurora, CO
7 shared publications- Muna Qayed
Aflac Cancer and Blood Disorders Center, Emory University and Children's Healthcare of Atlanta, Atlanta, GA
7 shared publications - Snehit Prabhu
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
7 shared publications
Latest Publications
- 16 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (20) , 7115-7124
Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults
Precursor B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignant neoplasm. Relapsed or refractory (R/R) B-ALL carries a dismal prognosis. CD19-specific chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment, yet relapse rates among responders remain high, with 40% to 50% experiencing relapse after therapy. This underscores the need for improved strategies to predict and prevent relapses after CAR T-cell therapy. This study reports the impact of peripheral blasts at the time of apheresis on outcomes in pediatric and young adult patients with R/R B-ALL treated with CD19-specific CAR T-cell therapy. A multi-institutional cohort of 162 patients from the Pediatric Real-World CAR Consortium was retrospectively analyzed. Key outcomes, such as day 28 response, event-free survival (EFS), and overall survival (OS), were evaluated based on the presence vs absence of peripheral blasts at apheresis. Although response at day 28 was comparable among peripheral blast groups in this cohort, the presence of peripheral blasts at apheresis was associated with inferior EFS (27% vs 55% at 12 months) and OS (55% vs 78% at 12 months). However, this association was confounded by disease burden at the time of infusion. In multivariable analysis, higher blast percentage at apheresis was not associated with an increased hazard of death (hazard ratio, 1.11; 95% confidence interval, 0.93-1.33; P = .25). These findings suggest that the association between peripheral blasts at apheresis and inferior survival is largely influenced by disease burden at infusion.
- 16 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (20) , 7115-7124
Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults
Precursor B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignant neoplasm. Relapsed or refractory (R/R) B-ALL carries a dismal prognosis. CD19-specific chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment, yet relapse rates among responders remain high, with 40% to 50% experiencing relapse after therapy. This underscores the need for improved strategies to predict and prevent relapses after CAR T-cell therapy. This study reports the impact of peripheral blasts at the time of apheresis on outcomes in pediatric and young adult patients with R/R B-ALL treated with CD19-specific CAR T-cell therapy. A multi-institutional cohort of 162 patients from the Pediatric Real-World CAR Consortium was retrospectively analyzed. Key outcomes, such as day 28 response, event-free survival (EFS), and overall survival (OS), were evaluated based on the presence vs absence of peripheral blasts at apheresis. Although response at day 28 was comparable among peripheral blast groups in this cohort, the presence of peripheral blasts at apheresis was associated with inferior EFS (27% vs 55% at 12 months) and OS (55% vs 78% at 12 months). However, this association was confounded by disease burden at the time of infusion. In multivariable analysis, higher blast percentage at apheresis was not associated with an increased hazard of death (hazard ratio, 1.11; 95% confidence interval, 0.93-1.33; P = .25). These findings suggest that the association between peripheral blasts at apheresis and inferior survival is largely influenced by disease burden at infusion.
- 24 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6422-6434
HLH-like syndromes associate with increased risk of death and CD19− relapse after CAR T in pediatric B-ALL
We previously reported poor long-term outcomes in patients with B-acute lymphoblastic leukemia (B-ALL) who developed hemophagocytic lymphohistiocytosis (HLH)–like toxicities (HLH-LT) after treatment with tisagenlecleucel. Since then, a consensus definition, immune effector cell–associated HLH-like syndrome (IEC-HS), was developed. Here, we report results from a multicenter retrospective study of children and young adults with B-ALL treated with tisagenlecleucel between 2018 and 2023, describing the incidence, diagnostic overlap, clinical phenotypes, and associated long-term outcomes of HLH-like syndromes. Of 154 tisagenlecleucel recipients, 14.9% met IEC-HS criteria, 21.4% met HLH-LT criteria, and 13% were identified as having HLH by treating institutions in the electronic health record; 10% met all definitions. Each HLH-like syndrome was associated with shortened overall survival and event-free survival, adjusting for baseline disease burden (P< .0001). Those with any HLH-like syndrome experienced 1-year cumulative incidence of nonresponse/relapse of 60% (95% confidence interval [CI], 43.1-76.9) vs 28.2% (95% CI, 20.0-36.5), P< .001, and nonrelapse mortality of 11.4% (95% CI, 0.7-22.1) vs 0% (95% CI, 0-0), P< .001, compared with those without. In those with high disease burden, patients with any HLH-like syndrome had a 1-year cumulative incidence of CD19− relapse of 65.2% (95% CI, 44.7-85.8) vs 2% (95% CI, 0-6.4) in those with no HLH-like syndrome, P< .001. Furthermore, adjusting for disease burden, any HLH-like syndrome was independently predictive of CD19− relapse with a hazard ratio of 8.10 (95% CI, 3.6-18.4), P< .001. These findings demonstrate partial definitional overlap of HLH-like syndromes and the prognostic significance of IEC-HS and identify CD19− relapse and nonrelapse mortality as key outcome drivers.
- 24 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6422-6434
HLH-like syndromes associate with increased risk of death and CD19− relapse after CAR T in pediatric B-ALL
We previously reported poor long-term outcomes in patients with B-acute lymphoblastic leukemia (B-ALL) who developed hemophagocytic lymphohistiocytosis (HLH)–like toxicities (HLH-LT) after treatment with tisagenlecleucel. Since then, a consensus definition, immune effector cell–associated HLH-like syndrome (IEC-HS), was developed. Here, we report results from a multicenter retrospective study of children and young adults with B-ALL treated with tisagenlecleucel between 2018 and 2023, describing the incidence, diagnostic overlap, clinical phenotypes, and associated long-term outcomes of HLH-like syndromes. Of 154 tisagenlecleucel recipients, 14.9% met IEC-HS criteria, 21.4% met HLH-LT criteria, and 13% were identified as having HLH by treating institutions in the electronic health record; 10% met all definitions. Each HLH-like syndrome was associated with shortened overall survival and event-free survival, adjusting for baseline disease burden (P< .0001). Those with any HLH-like syndrome experienced 1-year cumulative incidence of nonresponse/relapse of 60% (95% confidence interval [CI], 43.1-76.9) vs 28.2% (95% CI, 20.0-36.5), P< .001, and nonrelapse mortality of 11.4% (95% CI, 0.7-22.1) vs 0% (95% CI, 0-0), P< .001, compared with those without. In those with high disease burden, patients with any HLH-like syndrome had a 1-year cumulative incidence of CD19− relapse of 65.2% (95% CI, 44.7-85.8) vs 2% (95% CI, 0-6.4) in those with no HLH-like syndrome, P< .001. Furthermore, adjusting for disease burden, any HLH-like syndrome was independently predictive of CD19− relapse with a hazard ratio of 8.10 (95% CI, 3.6-18.4), P< .001. These findings demonstrate partial definitional overlap of HLH-like syndromes and the prognostic significance of IEC-HS and identify CD19− relapse and nonrelapse mortality as key outcome drivers.
- 23 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6395-6406
Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL
Inotuzumab ozogamicin (InO) is a humanized, anti-CD22 antibody–drug conjugate with demonstrated use in the treatment of children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Sinusoidal obstruction syndrome (SOS), a life-threatening complication of hematopoietic stem cell transplant (HSCT), arises from injury to the sinusoidal endothelium and occurs at higher frequency and severity after treatment with InO. Defibrotide is widely used in the treatment of transplant-associated SOS; however, its role in prophylaxis is less clear. In this single-center retrospective analysis, we evaluated all children, adolescents, and young adults with relapsed or refractory B-ALL who underwent HSCT at our institution from 2016 to 2024 and compared outcomes between those who received InO during reinduction before HSCT with those who did not. In addition, we evaluated our institutional practice of employing defibrotide as SOS prophylaxis during HSCT for those with prior receipt of InO. Among children treated with InO, we found that 81% of this heavily pretreated population received InO as the last therapy before HSCT. We found no increase in nonrelapse mortality during HSCT in patients with previous receipt of InO. Among those who received defibrotide prophylaxis, we observed an incidence of transplant-related SOS similar to that observed among patients who did not receive InO during reinduction. Defibrotide prophylaxis was well tolerated, with low rates of adverse events and discontinuation. These results support the use of InO for children with relapsed or refractory B-ALL and suggest that defibrotide prophylaxis may reduce the incidence of SOS during HSCT after InO.
- 23 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6395-6406
Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL
Inotuzumab ozogamicin (InO) is a humanized, anti-CD22 antibody–drug conjugate with demonstrated use in the treatment of children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Sinusoidal obstruction syndrome (SOS), a life-threatening complication of hematopoietic stem cell transplant (HSCT), arises from injury to the sinusoidal endothelium and occurs at higher frequency and severity after treatment with InO. Defibrotide is widely used in the treatment of transplant-associated SOS; however, its role in prophylaxis is less clear. In this single-center retrospective analysis, we evaluated all children, adolescents, and young adults with relapsed or refractory B-ALL who underwent HSCT at our institution from 2016 to 2024 and compared outcomes between those who received InO during reinduction before HSCT with those who did not. In addition, we evaluated our institutional practice of employing defibrotide as SOS prophylaxis during HSCT for those with prior receipt of InO. Among children treated with InO, we found that 81% of this heavily pretreated population received InO as the last therapy before HSCT. We found no increase in nonrelapse mortality during HSCT in patients with previous receipt of InO. Among those who received defibrotide prophylaxis, we observed an incidence of transplant-related SOS similar to that observed among patients who did not receive InO during reinduction. Defibrotide prophylaxis was well tolerated, with low rates of adverse events and discontinuation. These results support the use of InO for children with relapsed or refractory B-ALL and suggest that defibrotide prophylaxis may reduce the incidence of SOS during HSCT after InO.
- Open Access
- 31 December 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (1) , 106-110
Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel
- 31 December 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (1) , 106-110
Open AccessLiberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel
- Top Cited PapersOpen Access
- 17 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5249-5262
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry
Since the first approval of tisagenlecleucel in 2017, pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) may receive this CD19-directed chimeric antigen receptor T-cell therapy. We report real-world data from the Center for International Blood and Marrow Transplant Research (>2.5 years of follow-up). As of 4 May 2022, 768 patients with B-ALL had received tisagenlecleucel. Patients aged ≥18 and <18 years of age (including those <3 years) were treated during first relapse (26.6% and 26.7% [<3 years, 44.8%], respectively) or primary refractory disease (12.4% and 12.1% [<3 years, 15.5%], respectively) with 17.6% and 11.6% (<3 years, 13.8%), respectively, having high disease burden (≥50% bone marrow [BM] blasts) and 20.2% and 20.2% (0 to <5% BM blasts). Among patients with ≥12 months postinfusion follow-up (n = 578; median follow-up, 32.1 months), the best overall response of complete remission/complete remission with incomplete blood count recovery was 86.0%. The 12-month relapse-free survival (RFS) and overall survival (OS) were 61.8% and 79.4%, respectively, whereas the 24-month RFS and OS were 50.3% and 63.8%, respectively. Age (<18 years) and disease burden (<50% BM blasts) were associated with better outcomes. Previous inotuzumab therapy and KMT2A rearrangement were associated with worse outcomes. Older patients (≥18 years) experienced a higher rate of any-grade cytokine release syndrome (CRS) associated with higher disease burden before infusion. Any-grade CRS and neurotoxicity were lower in patients aged <3 years. Extended follow-up continues to demonstrate high rates of RFS and favorable safety in this population.
- 17 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5249-5262
Top Cited PapersOpen AccessReal-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry
Since the first approval of tisagenlecleucel in 2017, pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) may receive this CD19-directed chimeric antigen receptor T-cell therapy. We report real-world data from the Center for International Blood and Marrow Transplant Research (>2.5 years of follow-up). As of 4 May 2022, 768 patients with B-ALL had received tisagenlecleucel. Patients aged ≥18 and <18 years of age (including those <3 years) were treated during first relapse (26.6% and 26.7% [<3 years, 44.8%], respectively) or primary refractory disease (12.4% and 12.1% [<3 years, 15.5%], respectively) with 17.6% and 11.6% (<3 years, 13.8%), respectively, having high disease burden (≥50% bone marrow [BM] blasts) and 20.2% and 20.2% (0 to <5% BM blasts). Among patients with ≥12 months postinfusion follow-up (n = 578; median follow-up, 32.1 months), the best overall response of complete remission/complete remission with incomplete blood count recovery was 86.0%. The 12-month relapse-free survival (RFS) and overall survival (OS) were 61.8% and 79.4%, respectively, whereas the 24-month RFS and OS were 50.3% and 63.8%, respectively. Age (<18 years) and disease burden (<50% BM blasts) were associated with better outcomes. Previous inotuzumab therapy and KMT2A rearrangement were associated with worse outcomes. Older patients (≥18 years) experienced a higher rate of any-grade cytokine release syndrome (CRS) associated with higher disease burden before infusion. Any-grade CRS and neurotoxicity were lower in patients aged <3 years. Extended follow-up continues to demonstrate high rates of RFS and favorable safety in this population.
- Open Access
- 14 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (19) , 5070-5084
Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel
Hematotoxicity is the most frequent severe toxicity after chimeric antigen receptor T-cell (CAR-T) therapy. However, limited data exist on risk factors and outcomes for hematotoxicity for children and young adults (CAYAs) with B-acute lymphoblastic leukemia treated with tisagenlecleucel. We conducted a multi-institutional study involving 326 CAYAs, with 144 evaluable in an initial training cohort and 141 evaluable in a validation cohort, through the Pediatric Real-World CAR Consortium to characterize the incidence and outcomes of prolonged severe neutropenia (PSN) and to develop a predictive risk score for PSN, tailored for use in this population. The incidence of PSN, defined as an absolute neutrophil count of <0.5 x 103 cells per μL for ≥30 days, was 15.3% in the initial training cohort and 21% in the validation cohort. Development of PSN was associated with inferior overall survival (P < .001), relapse-free survival (P = .01), higher nonrelapse mortality (P = .003), and a greater risk of infections within 30 days (P = .03). Multivariable penalized regression analysis identified key risk factors for PSN, which included preinfusion C-reactive protein and bone marrow disease burden, and postinfusion peak ferritin and occurrence of severe cytokine release syndrome, which were used to create the CytoRisk score. In the validation cohort, the CytoRisk score discriminated between patients with and without PSN (area under the curve, 0.90; specificity, 93%; sensitivity, 71%; positive predictive value, 74%; and negative predictive value, 92%). The CytoRisk score may be used to a priori identify patients at highest risk of PSN and overall worse outcomes.
- 14 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (19) , 5070-5084
Open AccessCharacterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel
Hematotoxicity is the most frequent severe toxicity after chimeric antigen receptor T-cell (CAR-T) therapy. However, limited data exist on risk factors and outcomes for hematotoxicity for children and young adults (CAYAs) with B-acute lymphoblastic leukemia treated with tisagenlecleucel. We conducted a multi-institutional study involving 326 CAYAs, with 144 evaluable in an initial training cohort and 141 evaluable in a validation cohort, through the Pediatric Real-World CAR Consortium to characterize the incidence and outcomes of prolonged severe neutropenia (PSN) and to develop a predictive risk score for PSN, tailored for use in this population. The incidence of PSN, defined as an absolute neutrophil count of <0.5 x 103 cells per μL for ≥30 days, was 15.3% in the initial training cohort and 21% in the validation cohort. Development of PSN was associated with inferior overall survival (P < .001), relapse-free survival (P = .01), higher nonrelapse mortality (P = .003), and a greater risk of infections within 30 days (P = .03). Multivariable penalized regression analysis identified key risk factors for PSN, which included preinfusion C-reactive protein and bone marrow disease burden, and postinfusion peak ferritin and occurrence of severe cytokine release syndrome, which were used to create the CytoRisk score. In the validation cohort, the CytoRisk score discriminated between patients with and without PSN (area under the curve, 0.90; specificity, 93%; sensitivity, 71%; positive predictive value, 74%; and negative predictive value, 92%). The CytoRisk score may be used to a priori identify patients at highest risk of PSN and overall worse outcomes.
- Open Access
- 18 May 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (8) , 812.e1-812.e11
Effects of Total Body Irradiation on Hematopoietic Cell Transplantation Outcomes in Pediatric Acute Myeloid Leukemia with Prior Central Nervous System Involvement
- 18 May 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (8) , 812.e1-812.e11
Open AccessEffects of Total Body Irradiation on Hematopoietic Cell Transplantation Outcomes in Pediatric Acute Myeloid Leukemia with Prior Central Nervous System Involvement
- Open Access
- 28 April 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (8) , 517.e1-517.e12
Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy
- 28 April 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (8) , 517.e1-517.e12
Open AccessImmune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy
- Open Access
- 24 March 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (6) , 356.e1-356.e7
Access to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphobastic Leukemia Patients
- 24 March 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (6) , 356.e1-356.e7
Open AccessAccess to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphobastic Leukemia Patients
- Open Access
- 10 February 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (5) , 338.e1-338.e6
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials
- 10 February 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (5) , 338.e1-338.e6
Open AccessMulticenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials